Treatment Program for Anemia in AIDS Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: R W Johnson Pharmaceutical Research Institute
• Treatments: Epoetin Alfa

Criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

• Life expectancy < 3 months.

• = or < grade 4 performance score.

• AIDS-related dementia.

• Uncontrolled hypertension.

• Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients with the following are excluded:

• Life expectancy < 3 months.

• = or < grade 4 performance score.

• AIDS-related dementia.

• Uncontrolled hypertension.

• Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients must have:

• A clinical diagnosis of AIDS.

• Hematocrit < 30 percent.

• Endogenous serum erythropoietin level = or < 500 U/ml.

• A life expectancy = or > 3 months.

• > Grade 4 performance score.